A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female patients aged greater than or equal to (\>=) 18 years at the time of signing informed consent. * Patients diagnosed with T2D and receiving treatment with premix insulin for at least 12 weeks (3 months) based on local clinical guidelines. * Switched to treatment with IDegLira from previous treatment of premix insulins. The decision to initiate treatment with IDegLira must be independently from the decision to enrol in the study. * Available and documented HbA1c collected within 12 weeks prior to initiation of IDegLira. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Participation in any other T2D clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to initiation of IDegLira. * Previous treatment with IDegLira. * Patients diagnosed with Type 1 diabetes mellitus. * Female who is known to be pregnant, breastfeeding or intends to become pregnant during the conduct of the study. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the IDegLira label in Croatia.